FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017155369> ?p ?o ?g. }

• W2017155369 endingPage "S223" @default.
• W2017155369 startingPage "S223" @default.
• W2017155369 abstract "865 Some patients with type 1 diabetes mellitus and early retinopathy and nephropathy (proteinuria but preserved function) seek a pancreas transplant alone (PTA) to prevent blindness and end stage renal failure (ESRD). The need to take nephrotoxic immunosuppressive therapy has tempered the enthusiasm of providers. This analysis determines how effective PTA should be to warrant transplantation before irreversible end organ disease develops. The model assumes that diabetic patient mortality increases with age and level of renal impairment. Development of blindness and rate of deterioration in renal function were taken from the DCCT model (JAMA 1996). The model also assumes a 3-4% peri-operative surgical mortality, an increase risk of death with immunosuppressive therapy (infection and cancer), forestalls blindness and ESRD only with normal pancreas function, did not alter cardiovascular disease, and may induce ESRD from nephrotoxic therapy. The model predicts that with an overall pancreas graft life expectancy of 10 years, a 3.2 year patient survival advantage could accrue to IDDM patients, despite the up front mortality from surgery and a 20% higher annual mortality from immunosuppressive therapy. This strategy could result in a 50% reduction in blindness and 27% reduction in ESRD. In a sensitivity analysis, a 1% annual incidence of ESRD from nephrotoxicity would limit the gain in patient survival to 1.9 years and a 2.7% annual incidence of ESRD from nephrotoxicity would negate any survival benefit from PTA. Shorter PTA graft expectancy, transplanting at earlier stages of disease, transplanting in patients with slower transitions from proteinuria to ESRD, or assuming PTA has less of an impact on preventing blindness would also reduce benefit. Incorporating reasonable costs, utilities and discount rates, the calculated cost/quality life year gained for PTA could be as low as $46,000/quality adjusted life year. PTA increased to $78,500/quality adjusted life year with a 1% annual incidence of ESRD from drug toxicity. This model suggests that PTA may be a reasonable option in more patients than is currently recognized. Criteria for patient selection should include risk for progression to blindness and ESRD, improvement in quality of life with pancreas function and expected reduction in quality of life with blindness and ESRD. The use of non-nephrotoxic agents (rapamycin, IL-2 receptor antibodies and MMF) along with calcineurin inhibitor sparing protocols, should have an important impact on implementing studies of this option." @default.
• W2017155369 created "2016-06-24" @default.
• W2017155369 creator A5026123744 @default.
• W2017155369 creator A5030962427 @default.
• W2017155369 creator A5044516010 @default.
• W2017155369 creator A5079777886 @default.
• W2017155369 date "1999-04-01" @default.
• W2017155369 modified "2023-10-18" @default.
• W2017155369 title "ESTIMATING THE BENEFITS OF EARLY PANCREAS ONLY TRANSPLANTATION IN IDDM: A THEORETICAL ANALYSIS" @default.
• W2017155369 doi "https://doi.org/10.1097/00007890-199904150-00889" @default.
• W2017155369 hasPublicationYear "1999" @default.
• W2017155369 type Work @default.
• W2017155369 sameAs 2017155369 @default.
• W2017155369 citedByCount "0" @default.
• W2017155369 crossrefType "journal-article" @default.
• W2017155369 hasAuthorship W2017155369A5026123744 @default.
• W2017155369 hasAuthorship W2017155369A5030962427 @default.
• W2017155369 hasAuthorship W2017155369A5044516010 @default.
• W2017155369 hasAuthorship W2017155369A5079777886 @default.
• W2017155369 hasBestOaLocation W20171553691 @default.
• W2017155369 hasConcept C126322002 @default.
• W2017155369 hasConcept C134018914 @default.
• W2017155369 hasConcept C141071460 @default.
• W2017155369 hasConcept C159641895 @default.
• W2017155369 hasConcept C2778064082 @default.
• W2017155369 hasConcept C2779134260 @default.
• W2017155369 hasConcept C2780303639 @default.
• W2017155369 hasConcept C2911091166 @default.
• W2017155369 hasConcept C3019040382 @default.
• W2017155369 hasConcept C555293320 @default.
• W2017155369 hasConcept C71924100 @default.
• W2017155369 hasConceptScore W2017155369C126322002 @default.
• W2017155369 hasConceptScore W2017155369C134018914 @default.
• W2017155369 hasConceptScore W2017155369C141071460 @default.
• W2017155369 hasConceptScore W2017155369C159641895 @default.
• W2017155369 hasConceptScore W2017155369C2778064082 @default.
• W2017155369 hasConceptScore W2017155369C2779134260 @default.
• W2017155369 hasConceptScore W2017155369C2780303639 @default.
• W2017155369 hasConceptScore W2017155369C2911091166 @default.
• W2017155369 hasConceptScore W2017155369C3019040382 @default.
• W2017155369 hasConceptScore W2017155369C555293320 @default.
• W2017155369 hasConceptScore W2017155369C71924100 @default.
• W2017155369 hasIssue "7" @default.
• W2017155369 hasLocation W20171553691 @default.
• W2017155369 hasLocation W20171553692 @default.
• W2017155369 hasOpenAccess W2017155369 @default.
• W2017155369 hasPrimaryLocation W20171553691 @default.
• W2017155369 hasRelatedWork W1506615488 @default.
• W2017155369 hasRelatedWork W2003202813 @default.
• W2017155369 hasRelatedWork W2058481273 @default.
• W2017155369 hasRelatedWork W2113407187 @default.
• W2017155369 hasRelatedWork W2239798061 @default.
• W2017155369 hasRelatedWork W2333552823 @default.
• W2017155369 hasRelatedWork W2468847545 @default.
• W2017155369 hasRelatedWork W2917493079 @default.
• W2017155369 hasRelatedWork W3216147135 @default.
• W2017155369 hasRelatedWork W4206771823 @default.
• W2017155369 hasVolume "67" @default.
• W2017155369 isParatext "false" @default.
• W2017155369 isRetracted "false" @default.
• W2017155369 magId "2017155369" @default.
• W2017155369 workType "article" @default.